Neovascularization is the formation of new blood vessels, and it sits at the center of processes ranging from wound healing to cancer growth. Your body builds new vasculature constantly: after a cut, during exercise, throughout every menstrual cycle. But the same machinery that repairs tissue can also feed tumors, destroy vision, and destabilize arterial plaques. Whether neovascularization helps or harms depends entirely on context, and understanding that distinction has reshaped how doctors treat some of the most common diseases in the world.
How New Blood Vessels Actually Form
The term “neovascularization” is an umbrella that covers several distinct biological processes. The most commonly discussed is angiogenesis, where new capillaries sprout from existing blood vessels. This is triggered primarily by low oxygen levels in tissue. A separate process, arteriogenesis, involves the remodeling of small pre-existing connections between arteries into fully functional, larger-diameter vessels, and it is driven not by oxygen deprivation but by physical forces like the shear stress of blood flowing against vessel walls.1PubMed Central. Arteriogenesis versus angiogenesis: similarities and differences A third process, vasculogenesis, involves the creation of blood vessels from precursor cells and is most active during embryonic development, though it plays a limited role in adults too.
These distinctions matter because treatments designed to block one pathway may not affect the others. A drug that targets angiogenesis in a tumor, for instance, does nothing to stop arteriogenesis. In wound healing, all three processes can work together: angiogenesis builds the initial capillary network, vasculogenesis contributes precursor cells, and arteriogenesis expands existing arterial connections to restore blood flow to the damaged area.2PubMed. Neovascularisation in wound healing
The Molecular Engine Behind It
When cells don’t get enough oxygen, they activate a protein called HIF-1 (hypoxia-inducible factor-1), which functions as a master switch for blood vessel growth. HIF-1 turns on a cascade of genes, the most important of which produces VEGF (vascular endothelial growth factor). VEGF is the primary signal that tells nearby blood vessel cells to start dividing and migrating toward the oxygen-starved tissue.3PubMed Central. Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies This same HIF-1/VEGF pathway operates whether the trigger is a healing wound, a growing embryo, or a tumor starving for nutrients.
Experiments that block HIF-1 activity directly show that doing so reduces VEGF production and suppresses the formation of new blood vessels driven by low oxygen, confirming that HIF-1 is not just involved but required for the process.4PubMed. Hypoxia inducible factor-1α/vascular endothelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced angiogenesis in lung cancer HIF-1 also works with other growth signals, including placental growth factor and angiopoietins, to fine-tune the process. This redundancy is one reason why blocking just one signal often fails to stop neovascularization completely.
When New Blood Vessels Are Exactly What You Need
Neovascularization is essential for wound repair. When skin is cut or burned, the damaged area loses its blood supply. New capillaries sprouting into the wound bed deliver oxygen and nutrients to the cells rebuilding tissue.5PubMed Central. Vascular Endothelial Growth Factor and Angiogenesis in the Regulation of Cutaneous Wound Repair Without adequate angiogenesis, wounds stall. This is a major reason why chronic wounds in people with diabetes or poor circulation are so difficult to heal: the angiogenic response is impaired, and the wound bed can’t support the cellular activity needed for repair.
Exercise is another powerful driver. During physical activity, working muscles release signaling molecules that stimulate blood vessel growth in the surrounding tissue. These signals activate endothelial cells (the cells lining blood vessels) and recruit precursor cells that contribute to vascular regeneration.6PubMed Central. Exercise and Ischemia-Activated Pathways in Limb Muscle Angiogenesis and Vascular Regeneration The repeated exposure to increased blood flow and shear stress during regular exercise training alters the gene activity in vessel cells, gradually expanding the vascular network and improving blood flow regulation. The magnitude of this remodeling is tissue-specific, with the degree of new vessel growth linked to factors like whether the muscle is also growing in size.7PubMed. Molecular Mechanisms for Exercise Training-Induced Changes in Vascular Structure and Function: Skeletal Muscle, Cardiac Muscle, and the Brain
Reproductive biology relies on neovascularization at every cycle. In the ovary, the corpus luteum (the structure that forms after ovulation) depends on rapid angiogenesis during the early phase of its life to build the blood supply it needs to produce progesterone. That vessel growth is completed by mid-cycle, and later, blood vessel regression helps the corpus luteum break down if pregnancy does not occur.8PubMed Central. Angiogenesis in the human corpus luteum Meanwhile, in the uterus, the endometrial lining rebuilds its vascular network after each menstrual period. Vessel elongation during the early proliferative phase and the growth and coiling of spiral arteries during the secretory phase demand substantial angiogenic activity.9Human Reproduction. Endometrial angiogenesis throughout the human menstrual cycle
How Tumors Hijack the Process
A solid tumor can only grow to about one or two millimeters in diameter before it outpaces the oxygen and nutrients available from nearby existing vessels. To grow beyond that size and to spread, a tumor must make what researchers call an “angiogenic switch,” tipping the local balance between signals that promote vessel growth and signals that suppress it. Tumors frequently do this by overproducing VEGF and other growth factors, essentially co-opting the same repair machinery your body uses for wound healing.10PubMed. Role of angiogenesis in tumor growth and metastasis
The blood vessels that tumors build are not normal. They tend to be disorganized, leaky, and poorly covered by the stabilizing cells (pericytes) that healthy vessels depend on. This leakiness creates a chaotic tumor environment where blood flow is uneven, oxygen delivery is patchy, and drug penetration is inconsistent. Ironically, the very vessels that sustain a tumor’s growth also make it harder to treat, because therapeutic drugs can’t reach all parts of the tumor evenly through its malformed vascular network. Vessels lacking pericyte coverage are especially prone to leakage; in one study of inflamed tissue, regions of remodeled capillaries with little or no pericyte coverage showed leakage roughly 24 times the normal baseline.11The American Journal of Pathology. Pericyte Requirement for Anti-Leak Action of Angiopoietin-1 and Vascular Remodeling in Sustained Inflammation
Neovascularization in the Eye
The eye is one of the places where unwanted neovascularization causes the most damage. In the “wet” form of age-related macular degeneration, new blood vessels grow from the layer beneath the retina, pushing through a membrane called Bruch’s membrane and invading the space under or within the retina itself. These new vessels are fragile and leak fluid and blood, distorting the macula, the part of the retina responsible for sharp central vision. The prevailing theory is that age-related thickening of Bruch’s membrane predisposes it to developing cracks that allow vessels from the underlying choroid layer to grow through, accompanied by chronic low-grade inflammation.12PubMed. Wet age-related macular degeneration
Multiple molecular pathways drive this process. VEGF is central, but other signaling systems contribute as well. Research in animal models has shown that blocking the mineralocorticoid receptor pathway can inhibit choroidal neovascularization through mechanisms independent of VEGF, partly by increasing production of a protein called decorin that strengthens the surrounding tissue matrix.13Nature Communications. Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration This is a reminder that VEGF-targeted treatments, while effective for many patients, do not address every pathway involved.
Diabetic retinopathy presents a related but distinct problem. In its advanced proliferative stage, new blood vessels grow on the surface of the retina rather than beneath it. These vessels are fragile and prone to bleeding into the eye’s interior, which can cause sudden vision loss. Recent imaging research suggests that the physical characteristics of this retinal neovascularization can predict who will develop complications. Eyes that went on to develop bleeding or traction-related retinal detachment had substantially larger areas of new vessel membrane compared to eyes that remained stable, and measuring total neovascular membrane area showed strong predictive accuracy for identifying high-risk eyes.14PubMed. Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors
Cardiovascular Disease and Plaque Instability
In atherosclerosis, neovascularization plays a quieter but potentially deadly role. Large arteries have their own tiny blood supply, small vessels called vasa vasorum that run through the vessel wall. As atherosclerotic plaques develop, new microvessels sprout into the plaque from these vasa vasorum. This neovascularization within plaques is concerning because the new vessels are fragile and can rupture, causing bleeding inside the plaque. These microhemorrhages destabilize the plaque, making it more likely to crack open and trigger a heart attack or stroke.15PubMed Central. Atherosclerosis and atheroma plaque rupture: normal anatomy of vasa vasorum and their role associated with atherosclerosis
This is one of the more counterintuitive aspects of neovascularization. In a healing wound, new blood vessels are lifesaving. Inside an arterial plaque, they are destabilizing. The same basic biology produces opposite clinical outcomes depending on location.
Anti-Angiogenic Therapies and Their Trade-Offs
Drugs that block VEGF signaling have become standard treatments in oncology and ophthalmology. In cancer, anti-angiogenic therapies aim to starve tumors by cutting off their blood supply. In wet macular degeneration and diabetic retinopathy, injections of anti-VEGF drugs into the eye reduce the leakage and growth of abnormal vessels, preserving or improving vision in many patients.
But these drugs have meaningful side effects precisely because VEGF is not just a tumor signal. It plays a role in maintaining healthy blood vessels throughout the body, particularly in the kidneys and cardiovascular system. Anti-VEGF therapies as a class can cause high blood pressure, protein leaking into the urine, damage to the small vessels of the kidneys, and in some cases heart failure.16PubMed Central. VEGF inhibition, hypertension, and renal toxicity The kidney effects are a particular challenge: kidney damage can force doctors to lower the dose of cancer treatment or delay cycles, potentially compromising how well the cancer is controlled.14PubMed. Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors In most cases, the high blood pressure can be managed with standard blood pressure medications, while proteinuria often requires adjusting the anti-angiogenic drug dosage.17PubMed Central. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
Treatment resistance adds another layer of complexity. Tumors often find workarounds. They can activate alternative molecular pathways that sustain vessel growth despite VEGF blockade, recruit supportive stromal cells from the surrounding tissue, or switch to other modes of obtaining blood supply entirely. These resistance mechanisms are categorized broadly into changes in VEGF-related pathways, activation of non-VEGF growth signals, and interactions with the stromal cells surrounding the tumor.18PubMed Central. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer This is why anti-angiogenic drugs are usually combined with other treatments like chemotherapy or immunotherapy rather than used alone.
Therapeutic Angiogenesis for Blocked Arteries
If anti-angiogenic therapy aims to shut down blood vessel growth, therapeutic angiogenesis flips the goal: it tries to stimulate new vessel formation in tissues starved by blocked arteries. This approach has attracted research attention for over two decades, particularly for peripheral artery disease, where narrowed arteries restrict blood flow to the legs, sometimes severely enough to threaten limb loss. Several strategies have been explored, including delivering angiogenic genes, injecting growth factor proteins directly, transplanting stem or progenitor cells, and using small-molecule drugs, with some approaches reaching clinical trials.19PubMed Central. Therapeutic angiogenesis-based strategy for peripheral artery disease
Similar work targets ischemic heart disease, where parts of the heart muscle receive inadequate blood flow. Therapeutic angiogenesis has shown the ability to regrow blood supply in ischemic heart tissue, reduce the expansion of dead tissue after a heart attack, and potentially avoid the need for bypass surgery or transplant. More recently, researchers have begun investigating cell-derived microvesicles and exosomes as a cell-free approach, which may avoid some of the complications of transplanting live cells.20PubMed Central. Approaches to therapeutic angiogenesis for ischemic heart disease
The clinical results so far have been mixed, which is why therapeutic angiogenesis has not yet become a routine treatment. Growing new blood vessels in a controlled, lasting way turns out to be harder than suppressing them. The new vessels sometimes regress once the growth signal fades, and coordinating multiple vessel types (capillaries, arterioles, and larger arteries) to form a functional network remains a challenge.
Tissue Engineering and Building Vessels From Scratch
Regenerative medicine faces a fundamental vascularization problem: any engineered tissue thicker than a couple of millimeters needs its own blood supply to survive after implantation. Without it, cells at the center of a tissue graft starve and die before the body’s own vessels can grow in. Researchers are tackling this by designing scaffold materials that promote blood vessel formation.
The mechanical properties of these scaffolds matter considerably. Adjusting stiffness, increasing surface roughness, and creating interconnected pore structures all encourage vessel-lining cells to organize into networks. Building hollow channels into scaffolds promotes the formation of patterned vascular networks that can connect with the patient’s own circulation after implantation.21PubMed Central. Mechanical strategies to promote vascularization for tissue engineering and regenerative medicine Biodegradable scaffold platforms offer another angle, providing temporary structural support while the body builds its own vascular network, then dissolving away once they are no longer needed.22PubMed Central. Vascular tissue engineering: biodegradable scaffold platforms to promote angiogenesis
This field is still largely preclinical, but it highlights a key theme: controlling neovascularization, whether promoting it or suppressing it, requires understanding the physical environment, not just the chemistry. Vessel-lining cells respond to the stiffness and texture of the surface they grow on, and different tissue types show different responses to the same mechanical forces.23PubMed. Cardiac and lung endothelial cells in response to fluid shear stress on physiological matrix stiffness and composition A scaffold designed for heart tissue cannot simply be repurposed for lung tissue and be expected to work the same way.
Mechanical Forces as Angiogenic Signals
The molecular side of neovascularization, the HIF-1/VEGF pathway, gets the most attention, but mechanical signals are equally important. Blood flowing through vessels exerts shear stress on the inner lining, and this physical force directly influences whether vessel cells start dividing and migrating. In experimental models, the number of cells that began invading surrounding tissue depended on the magnitude of shear stress applied to them, with a particular sweet spot producing maximal cell invasion. Meanwhile, the distance those cells migrated increased proportionally as shear stress increased.24PubMed Central. Fluid shear stress modulates endothelial cell invasion into three-dimensional collagen matrices
This interplay between mechanical and chemical signals helps explain why exercise is such a potent stimulus for vascular health. Working muscles demand more blood flow, which increases shear stress in the feeding vessels, which activates vessel growth pathways that then expand the vascular bed. It also explains why arteriogenesis, the remodeling of existing arterial connections, is driven by flow dynamics rather than oxygen deprivation. When one artery gets blocked, blood diverts through small collateral pathways, the increased shear stress in those pathways triggers remodeling, and over time they can enlarge enough to partially compensate for the blocked vessel.1PubMed Central. Arteriogenesis versus angiogenesis: similarities and differences This collateral remodeling is one reason why some people with gradually narrowing coronary arteries develop fewer symptoms than expected: their bodies have had time to build alternative routes.